SG11201705808XA - Glypican epitopes and uses thereof - Google Patents

Glypican epitopes and uses thereof

Info

Publication number
SG11201705808XA
SG11201705808XA SG11201705808XA SG11201705808XA SG11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA
Authority
SG
Singapore
Prior art keywords
glypican
epitopes
glypican epitopes
Prior art date
Application number
SG11201705808XA
Other languages
English (en)
Inventor
Douglas Campbell
Fuenmayor Irene Justiniano
Aline Nocon
Julie Soon
Quach Truong
Bradley Walsh
Sandra Wissmueller
Original Assignee
Minomic Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minomic Int Ltd filed Critical Minomic Int Ltd
Publication of SG11201705808XA publication Critical patent/SG11201705808XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201705808XA 2015-01-16 2015-01-16 Glypican epitopes and uses thereof SG11201705808XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2015/000019 WO2016112423A1 (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Publications (1)

Publication Number Publication Date
SG11201705808XA true SG11201705808XA (en) 2017-08-30

Family

ID=56405046

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705808XA SG11201705808XA (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Country Status (11)

Country Link
US (2) US20180002391A1 (es)
EP (1) EP3245219B1 (es)
JP (1) JP6735005B2 (es)
KR (1) KR102435383B1 (es)
CN (1) CN107531755B (es)
AU (1) AU2015376851B2 (es)
CA (1) CA2973771A1 (es)
DK (1) DK3245219T3 (es)
ES (1) ES2805085T3 (es)
SG (1) SG11201705808XA (es)
WO (1) WO2016112423A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2778100T3 (es) 2014-10-23 2020-08-07 Glyp Holdings Pty Ltd Anticuerpos monoclonales anti-gpc-1 y usos de los mismos
KR20170138530A (ko) * 2015-04-20 2017-12-15 미노믹 인터내셔널 리미티드 치료용 항체 및 이의 용도
EP3617231A4 (en) * 2017-04-28 2021-04-07 National University Corporation Kochi University ANTI-GPC-1 ANTIBODY
WO2020154150A1 (en) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN111187350A (zh) * 2019-12-30 2020-05-22 西安英创生物技术有限公司 一种与磷脂酰肌醇蛋白聚糖-1结合的抗原结合蛋白
WO2024083921A1 (en) 2022-10-19 2024-04-25 Centro Di Riferimento Oncologico Di Aviano Anti-gpc1 monoclonal antibody, therapeutic and diagnostic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU2422999A (en) * 1998-01-27 1999-08-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New members of the glypican gene family
WO2000023109A1 (en) * 1998-10-16 2000-04-27 The Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
EP1780273B1 (en) * 2001-06-22 2010-10-06 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
CN111925445A (zh) * 2004-07-09 2020-11-13 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8270389B2 (en) 2008-08-11 2012-09-18 Marvell International Ltd. Method of synchronization for low power idle
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用

Also Published As

Publication number Publication date
WO2016112423A1 (en) 2016-07-21
JP6735005B2 (ja) 2020-08-05
US20180002391A1 (en) 2018-01-04
AU2015376851A1 (en) 2017-07-27
KR102435383B1 (ko) 2022-08-24
EP3245219A4 (en) 2018-06-06
CN107531755A (zh) 2018-01-02
JP2018504903A (ja) 2018-02-22
EP3245219A1 (en) 2017-11-22
AU2015376851B2 (en) 2020-07-09
KR20170109584A (ko) 2017-09-29
ES2805085T3 (es) 2021-02-10
DK3245219T3 (da) 2020-06-29
CA2973771A1 (en) 2016-07-21
CN107531755B (zh) 2022-02-25
US20210107958A1 (en) 2021-04-15
EP3245219B1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
IL283321A (en) Antibodies against muc16 and their uses
IL285375A (en) Antibodies that bind to il-8 and their uses
HK1254861A1 (zh) 抗lag3抗體及其用途
IL258248A (en) Attraction Oligonucleotide Conjugates and Their Uses
HK1250238A1 (zh) 抗angptl8抗體及其用途
HK1255067A1 (zh) 抗c10orf54抗體及其用途
HK1243440A1 (zh) 抗白細胞介素-33抗體及其用途
IL247407A0 (en) Antibodies against egfrviii and their uses
HK1256381A1 (zh) 抗pacap抗體及其用途
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL251001B (en) Anti-il-25 antibodies and their uses
PT3292154T (pt) Anticorpos anti-her3 humano e seus usos
SG11201705808XA (en) Glypican epitopes and uses thereof
HK1247122A1 (zh) 組合及其用途
IL254241A0 (en) Etv2 and its uses
HK1254240A1 (zh) 抗羥腐胺賴氨酸抗體及其用途
AU2016041V (en) Primaris Diplotaxis tenuifolia
HK1202024A2 (en) Umbrella shape direction valve